RG
KDNY

Redmile Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Redmile Group’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,087
Closed -$294K – 58
2015
Q4 		$294K Sell
2,087
-1,124
-35% -$153K 0.02% 52
2015
Q3 		$311K Sell
3,211
-9,117
-74% -$1.09M 0.02% 54
2015
Q2 		$1.87M Buy
+12,328
New +$2.04M 0.15% 52

Other funds holding KDNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.23B AUM 51.32% 1-Year Est. Return

Redmile Group's KDNY Position: Q1 2016 in Review

Redmile Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2016, closing a stake of 2,087 shares — an estimated $294K sold.

Redmile Group first reported a position in KDNY in Q2 2015 and held it in 3 quarters. The position peaked at $1.87M in Q2 2015. 89 funds tracked by Wall St. Rank hold KDNY as of Q1 2016.

  • Redmile Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Redmile Group sold 2,087 Chinook Therapeutics, Inc. Common Stock shares in Q1 2016, an estimated $294K.
  • Redmile Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 3 quarters.
  • Redmile Group's Chinook Therapeutics, Inc. Common Stock position peaked at $1.87M in Q2 2015.
  • 89 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2016.

Based on Redmile Group's 13F filing for Q1 2016, filed 16 May 2016.